BARINTHUS BIOTHERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.43 USD | +9.21% |
|
+3.40% | -34.15% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 94.57M |
|---|---|---|---|---|---|
| Net income 2024 * | -82M | Net income 2025 * | -113M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 56.22M | Net cash position 2025 * | 3.79M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.38
x | P/E ratio 2025 * |
-1.05
x | Employees | 130 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.72% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +9.21% | ||
| 1 week | +3.40% | ||
| Current month | +18.53% | ||
| 1 month | -3.96% | ||
| 3 months | -3.19% | ||
| 6 months | -17.63% | ||
| Current year | -34.15% |
1 week
2.20
2.43
1 month
1.822.77
Current year
1.824.16
1 year
1.645.10
3 years
1.6417.99
5 years
1.6417.99
10 years
1.6417.99
| Managers | Title | Age | Since |
|---|---|---|---|
William Enright
CEO | Chief Executive Officer | 61 | 19-07-31 |
Gemma Brown
DFI | Director of Finance/CFO | 34 | 21-08-31 |
Nadège Pelletier
CTO | Chief Tech/Sci/R&D Officer | 46 | 23-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 21-02-28 |
William Enright
CEO | Chief Executive Officer | 61 | 19-07-31 |
Anne Phillips
BRD | Director/Board Member | 70 | 21-02-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 2.43 | +9.21% | 5,829 |
| 24-05-15 | 2.225 | -4.09% | 9,472 |
| 24-05-14 | 2.32 | -1.07% | 6,553 |
| 24-05-13 | 2.345 | +0.43% | 7,495 |
| 24-05-10 | 2.335 | -0.64% | 8,563 |
Delayed Quote Nasdaq, May 16, 2024 at 04:30 pm EDT
More quotes
Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.43
USD
Average target price
7.4
USD
Spread / Average Target
+204.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.15% | 94.57M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +49.11% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- BRNS Stock
